| Item Type | Name |
|
Concept
|
Genotype
|
|
Academic Article
|
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
|
|
Academic Article
|
Gazing into a crystal ball-cancer therapy in the post-genomic era.
|
|
Academic Article
|
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
|
|
Academic Article
|
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
|
|
Academic Article
|
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
|
|
Academic Article
|
Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.
|
|
Academic Article
|
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
|
|
Academic Article
|
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
|
|
Academic Article
|
"Irinogenetics" and UGT1A: from genotypes to haplotypes.
|
|
Academic Article
|
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
|
|
Academic Article
|
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
|
|
Academic Article
|
Personalized medicine: building the GPS to take us there.
|
|
Academic Article
|
Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver.
|
|
Academic Article
|
Global gene expression as a function of germline genetic variation.
|
|
Academic Article
|
Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.
|
|
Academic Article
|
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
|
|
Academic Article
|
A pharmacogenetic study of vorinostat glucuronidation.
|
|
Academic Article
|
Vascular endothelial growth factor pathway.
|
|
Academic Article
|
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue.
|
|
Academic Article
|
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
|
|
Academic Article
|
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
|
|
Academic Article
|
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
|
|
Academic Article
|
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
|
|
Academic Article
|
Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
|
|
Academic Article
|
Pharmacogenetics and pharmacogenomics of anticancer agents.
|
|
Academic Article
|
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
|
|
Academic Article
|
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
|
|
Academic Article
|
UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.
|
|
Academic Article
|
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
|
|
Academic Article
|
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
|
|
Academic Article
|
CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality.
|
|
Academic Article
|
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
|
|
Academic Article
|
Meaningful use of pharmacogenetics.
|
|
Academic Article
|
Incorporating biomarkers into drug labeling.
|
|
Academic Article
|
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
|
|
Academic Article
|
Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project".
|
|
Academic Article
|
Establishment of CYP2D6 reference samples by multiple validated genotyping platforms.
|
|
Academic Article
|
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
|
|
Academic Article
|
Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.
|
|
Academic Article
|
Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.
|
|
Academic Article
|
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.
|
|
Academic Article
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.
|
|
Academic Article
|
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
|
|
Academic Article
|
Disease-drug database for pharmacogenomic-based prescribing.
|
|
Academic Article
|
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
|
|
Academic Article
|
ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.
|
|
Academic Article
|
Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.
|
|
Academic Article
|
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).
|
|
Academic Article
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
|
|
Academic Article
|
Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.
|
|
Academic Article
|
Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation.
|
|
Academic Article
|
A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes.
|
|
Academic Article
|
Pharmacogenomic-Based Decision Support to Predict Adherence to Medications.
|
|
Academic Article
|
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
|
|
Academic Article
|
Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib.
|
|
Academic Article
|
Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform.
|
|
Academic Article
|
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
|